drugset / Trial / NCT05579626
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
Phase 4
Enrolling by invitation
4000 enrolled
Seung-Whan Lee, M.D., Ph.D.
Yuhan Corporation · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have prediabetes.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ezetimibe | Unknown | 10 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 5 mg | Oral |
| Comparator | Rosuvastatin | Small molecule | 20 mg | Oral |